Background: During winter 2009 we treated with prolonged corticosteroid infusion eight consecutive patients affected by H1N1-virus infection and severe pneumonia. The most severe patient was a previously healthy 30-year-old man admitted to hospital because of bilateral pneumonia and severe acute respiratory failure. Method: H1N1-virus infection was detected by broncho-alveolar lavage performed on day 1. After some days following admission the patient was still in a life-threatening state, not responding to oseltamivir, protective mechanical ventilation and veno-arterial extracorporeal membrane oxygenation (ECMO).
Introduction
During the 2009 winter season, we successfully treated eight consecutive patients with influenza and severe hypoxaemia (PaO 2 :FiO 2 198±32) with prolonged low-dose methylprednisolone infusion (Table 1) . As a representative case, we report the beneficial addition of methylprednisolone infusion (1 mg/kg daily) in our most severe case of hypoxaemic respiratory failure. A 30-yearold man, previously a healthy mild smoker, was admitted to the hospital with fever (over 40 C), increasing dyspnoea, cough and bilateral infiltrates on chest radiograph. At admission, the patient underwent a broncho-alveolar lavage that confirmed H1N1 influenza A virus infection. Within 24 h, the patient rapidly developed acute respiratory distress syndrome (ARDS) with a PaO 2 :FiO 2 of 32 necessitating endotracheal intubation and mechanical ventilation (MV).
Initial treatment included oseltamivir (75 mg twice daily for the first 2 days and than 150 mg twice daily for 7 days) and broad-spectrum antimicrobials (i.e. meropenem, vancomycin and itraconazole). Corticosteroids were not initially added because the patient was admitted to a unit where the use of corticosteroids was not usual during H1N1-virus infection in accordance with World Health Organization (WHO) guidance on pandemic influenza [World Health Organization, 2009] . Despite prone ventilation with low tidal volume and high positive endexpiratory pressure (20 cm H 2 O), the patient failed to improve, and veno-arterial extra corporeal membrane oxygenation (ECMO) was initiated on day 3. As shown in Figure 1 , this intervention was not associated with improvements in sequential organ failure assessment and lung injury scores. On day 7, prolonged low-dose methylprednisolone infusion (1 mg/kg/day) was initiated as a rescue treatment. Within 3 days clinical conditions significantly improved and, after 6 and 10 days, respectively, of initiating methylprednisolone treatment, the patient was weaned from ECMO and MV (PaO 2 :FiO 2 460 on day 16).
Methylprednisolone treatment was associated with a reduction in C-reactive protein levels (from 134.95 mg/L on day 1, to 15.40 mg/L after 7 days, to 0.4 mg/L on day 14), and procalcitonin levels (respectively, 0.3, 3.8 and 0.2 mg/mL on days 1, 7 and 14). Infection surveillance was implemented during corticosteroid administration and paralysis was limited as much as possible.
Methylprednisolone was gradually tapered and the patient recovered with no significant adverse effects. 
Discussion
In previously healthy young individuals, ARDS caused by influenza A (H1N1) pneumonia may be fatal despite antiviral therapy [Uyeki et al. 2009 ]. In November 2009, WHO stated: 'highdose systemic corticosteroids . . . for viral pneumonitis are not recommended for use outside of the context of clinical trials' [World Health Organization, 2009 ]. This recommendation was made before the publication of Quispe-Laime's paper [Quispe-Laime et al. 2010] and did not take into consideration the literature on lowdose corticosteroid treatment including a recent meta-analysis [Tang et al. 2009 ] and expert recommendations [Marik et al. 2008 ].
According to our prior pneumonia experience [Confalonieri et al. 2005] , and the recent reports in the literature [Quispe-Laime et al. 2010; Tang et al. 2009; Carter, 2007] , we reasoned that most deaths in nonobese, previously healthy patients with severe H1N1 pneumonia might be prevented with prolonged low doses of corticosteroids (stress dose). The present case report shows that the addition of low-dose methylprednisolone acts as a disease-modifying treatment as shown by improvement in severity scores and findings of serial computed tomography scans performed before and during methylprednisolone infusion (Figure 1 ). Most recently, Kidd et al. [2009] reported a case of H1N1 severe pneumonitis that promptly improved with prolonged intravenous zanamivir and methylprednisolone. The authors encouraged future investigations on intravenous zanamivir both alone and in combination with methylprednisolone. The use of corticosteroid in patients with severe influenza H1N1 has been repeatedly cited in recent articles [Chien et al. 2010; Chang et al. 2010 (Table 2) , but standard dose regimen and steroids treatment outcome were rarely described. Nevertheless, we are convinced that the use of prolonged low doses of corticosteroids in the most severely ill patients in the presence of severe sepsis and/or acute lung injury (ALI)-ARDS is sufficiently supported by literature data. In fact, two recent meta-analyses [Annane et al. 2009; Tang et al. 2009 ] on prolonged glucocorticoid treatment in severe sepsis and ALI-ARDS concluded that prolonged low-to-moderate-dose glucocorticoid treatment is safe and associated with significant reduction in organ dysfunction scores, duration of intensive care unit stay and MV. However, a randomized trial in patients with severe pneumonia caused by H1N1 is needed to evaluate whether using prolonged low doses of corticosteroids may be definitively established in these patients.
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